Mind Medicine (MindMed) (MNMD) Competitors $9.22 -0.01 (-0.11%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$9.22 0.00 (0.00%) As of 09/5/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock MNMD vs. KYMR, XENE, AMRX, VKTX, ARWR, MOR, CRNX, RARE, NAMS, and HCMShould you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Kymera Therapeutics (KYMR), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Viking Therapeutics (VKTX), Arrowhead Pharmaceuticals (ARWR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), NewAmsterdam Pharma (NAMS), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Mind Medicine (MindMed) vs. Its Competitors Kymera Therapeutics Xenon Pharmaceuticals Amneal Pharmaceuticals Viking Therapeutics Arrowhead Pharmaceuticals MorphoSys Crinetics Pharmaceuticals Ultragenyx Pharmaceutical NewAmsterdam Pharma HUTCHMED Kymera Therapeutics (NASDAQ:KYMR) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Which has more risk & volatility, KYMR or MNMD? Kymera Therapeutics has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.48, indicating that its share price is 148% more volatile than the S&P 500. Which has higher valuation and earnings, KYMR or MNMD? Mind Medicine (MindMed) has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M66.09-$223.86M-$3.47-12.54Mind Medicine (MindMed)N/AN/A-$108.68M-$1.53-6.03 Do institutionals and insiders believe in KYMR or MNMD? 27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 2.5% of Mind Medicine (MindMed) shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is KYMR or MNMD more profitable? Mind Medicine (MindMed) has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat Mind Medicine (MindMed)'s return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-616.03% -31.60% -27.12% Mind Medicine (MindMed) N/A -50.24%-39.41% Do analysts recommend KYMR or MNMD? Kymera Therapeutics presently has a consensus price target of $58.76, indicating a potential upside of 35.06%. Mind Medicine (MindMed) has a consensus price target of $24.71, indicating a potential upside of 168.05%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 3.11Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media favor KYMR or MNMD? In the previous week, Kymera Therapeutics had 3 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 12 mentions for Kymera Therapeutics and 9 mentions for Mind Medicine (MindMed). Kymera Therapeutics' average media sentiment score of 1.28 beat Mind Medicine (MindMed)'s score of 1.09 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mind Medicine (MindMed) 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKymera Therapeutics and Mind Medicine (MindMed) tied by winning 8 of the 16 factors compared between the two stocks. Get Mind Medicine (MindMed) News Delivered to You Automatically Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNMD vs. The Competition Export to ExcelMetricMind Medicine (MindMed)MED IndustryMedical SectorNASDAQ ExchangeMarket Cap$701.53M$3.18B$5.83B$9.93BDividend YieldN/A2.26%6.70%4.52%P/E Ratio-6.0321.1076.1526.11Price / SalesN/A471.22564.25189.88Price / CashN/A45.7236.9959.28Price / Book2.879.8711.486.09Net Income-$108.68M-$53.42M$3.29B$266.51M7 Day Performance3.83%2.93%1.27%0.46%1 Month Performance-6.77%9.85%7.94%4.59%1 Year Performance55.09%15.74%62.94%26.04% Mind Medicine (MindMed) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNMDMind Medicine (MindMed)2.5488 of 5 stars$9.22-0.1%$24.71+168.1%+50.3%$701.53MN/A-6.0340News CoveragePositive NewsKYMRKymera Therapeutics3.2647 of 5 stars$41.82-5.2%$59.11+41.3%-6.6%$2.99B$47.07M-12.05170News CoveragePositive NewsXENEXenon Pharmaceuticals2.8074 of 5 stars$38.14-1.8%$53.20+39.5%-1.6%$2.94B$7.50M-10.74210News CoveragePositive NewsAnalyst ForecastOptions VolumeAMRXAmneal Pharmaceuticals3.4801 of 5 stars$9.28-3.2%$11.60+25.0%+13.8%$2.91B$2.85B928.938,100News CoveragePositive NewsVKTXViking Therapeutics4.3139 of 5 stars$25.85-0.6%$86.92+236.3%-51.3%$2.91BN/A-16.9020Positive NewsARWRArrowhead Pharmaceuticals3.9414 of 5 stars$20.71-2.9%$43.14+108.3%+25.1%$2.86B$3.55M-16.18400Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.9141 of 5 stars$30.09-2.7%$68.86+128.8%-30.1%$2.83B$1.04M-7.32210News CoveragePositive NewsRAREUltragenyx Pharmaceutical4.3862 of 5 stars$29.27-1.7%$81.50+178.4%-43.6%$2.82B$610.16M-5.291,294News CoveragePositive NewsAnalyst ForecastNAMSNewAmsterdam Pharma3.6341 of 5 stars$24.70-1.2%$41.55+68.2%+66.7%$2.78B$45.56M-15.254News CoverageInsider TradeHCMHUTCHMED2.1437 of 5 stars$15.93-1.1%$28.00+75.8%-9.5%$2.78B$602.20M0.001,811Gap Up Related Companies and Tools Related Companies KYMR Alternatives XENE Alternatives AMRX Alternatives VKTX Alternatives ARWR Alternatives MOR Alternatives CRNX Alternatives RARE Alternatives NAMS Alternatives HCM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNMD) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mind Medicine (MindMed) Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mind Medicine (MindMed) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
